Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors (SARMET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01391533|
Recruitment Status : Completed
First Posted : July 12, 2011
Last Update Posted : April 13, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
To determine the maximum tolerated dose (MTD) of SAR125844. To confirm safety profile of SAR125844 when administered as single agent at the MTD.
To evaluate the preliminary anti-tumoral effect of SAR125844 in patients with MET-gene amplified solid tumors (including sub-group of MET-amplified non-small cell lung cancer [NSCLC] patients) and in patients with Phospho-MET positive tumors without MET-gene amplification.
To characterize the global safety profile including cumulative toxicities. To evaluate the pharmacokinetic profile of SAR125844 in the proposed dosing schedule(s).
To assess preliminary antitumor activity in patients with measurable/evaluable disease, according to RECIST 1.1 criteria.
To explore the pharmacodynamic effects (PD) of SAR125844. To explore MET gene amplification status in Circulating Tumoral Cells (CTCs) and on tumor biopsies collected during the study, in the escalation part only.
To evaluate other pharmacodynamic biomarkers and help selection of patients who could benefit from SAR125844.
To explore MET-gene amplification status in circulating DNA.
|Condition or disease||Intervention/treatment||Phase|
|Malignant Solid Tumors||Drug: SAR125844||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||72 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic, First in Man Study, of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors|
|Study Start Date :||July 2011|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 2016|
Experimental: Dose Escalation
Dose escalation phase: The starting dose of SAR125844 will be 50 mg/m^2 up to 960 mg/m^2
Route of administration: intravenous
- Dose Escalation To determine the maximum tolerated dose (MTD) of SAR125844 [ Time Frame: At day 28 of Cycle 1 of each treated patient, DLT is assessed ]
- Expansion Cohorts To evaluate the preliminary anti-tumoral effect of SAR125844 [ Time Frame: Anticancer activity is assessed at Day 28 and then every 8 weeks thereafter up to an expected maximum of 2 years ]
- Number of patients with treatment emergent events [ Time Frame: Up to 2 years ]
- Assessment of PK parameter Cmax [ Time Frame: Up to 2 years ]
- Assessment of PK parameter AUCs [ Time Frame: Up to 2 years ]
- Assessment of PK parameter CL [ Time Frame: Up to 2 years ]
- Assessment of PD parameter ShedMET [ Time Frame: Up to 2 years ]
- Assessment of PD parameter HGF [ Time Frame: Up to 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
In the dose escalation part: patients with high MET tumor expression, evaluable or measurable solid tumors for which no standard therapy is available.
In the expansion cohorts: in the first cohort, patients with diagnosed MET gene amplified including NSCLC patients and measurable tumors for which no standard therapy is available will be eligible. In the second cohort, patients with advanced P-MET positive measurable solid tumor without MET- gene amplification for which no standard therapy is available will be eligible.
Patient less than 18 years old. ECOG performance status >2. Any serious active disease or co-morbid condition, which, in the opinion of the Investigator, may interfere with the safety or the compliance with the study.
Poor bone marrow reserve as defined by absolute neutrophil count <1.5 x 10^9/L or platelets <100 x 10^9/L.
Poor organ function as defined by one of the following:
- Total bilirubin >1.5 x ULN
- AST, ALT, alkaline phosphatase >2.5 x ULN or >5 x ULN in case of documented liver metastasis. Alkaline phosphatase up to 5 x ULN in case of osteolytic bone metastasis without liver metastases is allowed
- Serum creatinine >1.5 x ULN or
- Serum creatinine between 1.0 and 1.5 x ULN associated with calculated creatinine clearance <60 mL/min
- Proteinuria >500 mg/24H Pregnant or breast-feeding women. No use of effective birth control methods, when applicable. No measurable or evaluable tumor lesion in the Dose Escalation part, and no measurable lesions in the expansion cohorts.
Brain metastasis (other than totally resected or previously pre-irradiated and no progressive/relapsing) or lepto-meningeal carcinomatosis.
No resolution of any specific toxicities (excluding alopecia) related to any prior anti-cancer therapy to grade ≤1 according to the NCI CTCAE v.4.03.
Wash out period of less than 3 weeks from previous antitumor therapy or any investigational treatment (and less than 6 weeks in case of prior nitroso-urea and or mitomycin C treatment).
Any surgery with major risk of bleeding performed less than 10 days prior to study treatment administration.
Any other severe underlying medical conditions, which could impair the ability to participate in the study or the interpretation of its results.
Patients treated with potent CYP3A inhibitor unless it can be discontinued at least 2 weeks prior to study treatment or 5 elimination half-life, whichever is the longest.
Patients treated with potent and moderate CYP3A inducers unless it can be discontinued at least 2 weeks prior to study treatment or 5 elimination half-life, whichever is the longest. Patients treated with weak CYP3A inducers such as dexamethasone are eligible.
Known hypersensitivity or any adverse event related to the study drug excipient.
Prior treatment with any compound in the same class. Mean QTc interval prolongation.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01391533
|United States, Massachusetts|
|Investigational Site Number 840001|
|Boston, Massachusetts, United States, 02114|
|Investigational Site Number 250002|
|Dijon, France, 21079|
|Investigational Site Number 250001|
|Villejuif, France, 94805|
|Investigational Site Number 380004|
|Bologna, Italy, 40138|
|Investigational Site Number 380002|
|Milano, Italy, 20133|
|Investigational Site Number 380001|
|Milano, Italy, 20141|
|Investigational Site Number 724001|
|Barcelona, Spain, 08035|
|Investigational Site Number 724003|
|Madrid, Spain, 28040|
|Study Director:||Clinical Sciences & Operations||Sanofi|
|Other Study ID Numbers:||
2010-021398-36 ( EudraCT Number )
U1111-1117-9878 ( Other Identifier: UTN )
|First Posted:||July 12, 2011 Key Record Dates|
|Last Update Posted:||April 13, 2016|
|Last Verified:||April 2016|